Jazz Pharmaceuticals (JAZZ) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed United Therapeutics (UTHR) over the past year, gaining 61.5% versus a gain of 18.7%. Over five years, UTHR leads with a +184.8% price change compared with +58.1% for JAZZ. United Therapeutics is the larger company by market cap ($22.92 billion vs $14.10 billion), about 1.6 times the size.
On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.4x vs 15.8x for United Therapeutics). United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus -8.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JAZZ | UTHR |
|---|---|---|
| Share price | $217.24 | $534.35 |
| Market cap | $14.10B | $22.92B |
| 1-day change | -2.34% | +0.29% |
| YTD return | +30.85% | +9.34% |
| 1-year return | +61.45% | +18.68% |
| 5-year return | +58.10% | +184.80% |
| P/E ratio (TTM) | 14.89 | 19.14 |
| Forward P/E | 8.38 | 15.81 |
| EPS (TTM) | $14.59 | $27.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.27B | $3.18B |
| Revenue growth (YoY) | +4.88% | +10.61% |
| Net income (latest FY) | $-356.15M | $1.33B |
| Gross margin | — | 87.92% |
| Operating margin | -10.08% | 46.89% |
| Net margin | -8.35% | 41.94% |
| 52-week high | $266.38 | $609.35 |
| 52-week low | $128.80 | $409.07 |
| Distance from 52-week high | -18.45% | -12.31% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +35.56% | +21.58% |
| Average volume | 859.22K | 672.80K |
| Shares outstanding | 64.91M | 42.89M |
| Employees | 2,890 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed UTHR by 42.8 percentage points over the past year.
- United Therapeutics trades at a higher earnings multiple (19.1x vs 14.9x trailing P/E).
- United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus -8.3 cents for Jazz Pharmaceuticals.
- United Therapeutics grew revenue faster in its latest fiscal year (+10.61% vs +4.88%).
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
JAZZ vs UTHR FAQ
Which is bigger, Jazz Pharmaceuticals or United Therapeutics?
United Therapeutics (UTHR) is larger, with a market capitalization of $22.92B compared with $14.10B for Jazz Pharmaceuticals (JAZZ).
Which stock has performed better over the past year, JAZZ or UTHR?
JAZZ returned +61.45% over the past 12 months, compared with +18.68% for UTHR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, JAZZ or UTHR?
JAZZ has the lower trailing P/E at 14.9, versus 19.1 for UTHR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Jazz Pharmaceuticals and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.